Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/ cyclophosphamide (AC) in operable breast cancer: Analysis of response and tolerability in a randomised phase III trial (TOPIC 2)

S. Chua, Ian E. Smith*, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E.R. O'Brien, S. R. Ebbs, A. Hong, A. Wardley, T. Mughal, M. Verrill, D. Dubois, J. M. Bliss, W. Allum, G. Gui, S. Dean, C. Trask, M. KissinF. McKinna, A. Goodman, T. Howell, T. Guilliford, A. Golding, M. McIllmurray, J. Barrett, C. Charlton, C. Price, T. Iveson, S. O'Reilley, T. Perren, N. Mithal, P. Ellis, R. Allerton, D. Bloomfield, R. Agrawal, P. Murray, W. Pratt, N. Davidson, J. Mansi, D. Rea

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/ cyclophosphamide (AC) in operable breast cancer: Analysis of response and tolerability in a randomised phase III trial (TOPIC 2)'. Together they form a unique fingerprint.

Medicine & Life Sciences